CHMA Chiasma

Chiasma to Report Fourth Quarter 2020 Results on March 4

Chiasma to Report Fourth Quarter 2020 Results on March 4

Company to host conference call and webcast at 5:00 p.m. ET

NEEDHAM, Maine, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, March 4, 2021 at 5:00 pm Eastern Time to discuss financial results for the quarter and year ended December 31, 2020 and to provide a business update.

Conference Call Details

Thursday, March 4th @ 5:00 pm Eastern Time

Domestic:877-407-4018
International:201-689-8471
Conference ID:13715763
Webcast:

A live audio webcast of the call may also be accessed under "Events & Presentations" on the News & Investors section of the Company's website, /events-presentations. An archived replay of the webcast will be available on the Company’s website approximately two hours after the event. The archived webcast will be available for one year.

About Chiasma

Chiasma is a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company’s website at .

Investor Contact:

Ashley R. Robinson

LifeSci Advisors, LLC

617-775-5956

Media Relations:

Patrick Bursey

LifeSci Communications

646-876-4932



EN
25/02/2021

Underlying

CHMAChiasma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Chiasma

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.01
MASI Masimo Corporat...
XONE EXONE CO ... (+28)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

MASI MASIMO CORPORATION
XONE EXONE CO
SPLK SPLUNK INC.
RUN SUNRUN INC.
RGNX REGENXBIO INC.
REGN REGENERON PHARMACEUTICALS INC.
NRG NRG ENERGY INC.
LXRX LEXICON PHARMACEUTICALS INC.
LGND LIGAND PHARMACEUTICALS INCORPORATED
K KELLOGG COMPANY
EDIT EDITAS MEDICINE INC.
CHMA CHIASMA
BMRN BIOMARIN PHARMACEUTICAL INC.
AXSM AXSOME THERAPEUTICS
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
PI IMPINJ INC.
RETA REATA PHARMACEUTICALS INC. CLASS A
TNDM TANDEM DIABETES CARE
APPN APPIAN
RGCO RGC RESOURCES
SAIL SAILPOINT TECHNOLOGIES
APLT APPLIED THERAPEUTICS
NOVA SUNNOVA ENERGY INTERNATIONAL
VERO VENUS CONCEPT
MGNI MAGNITE INC
PCVX VAXCYTE
U UNITY SOFTWARE
MAXN MAXEON SOLAR TECHNOLOGIES
06/30/21 June 30, 2021 1 EN
 PRESS RELEASE
Free
CHMA CHIASMA

Chiasma Announces Submission of Marketing Authorization Application fo...

Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency Submission supported by previously announced data from Phase 3 MPOWERED™ study NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it has submitted a Marketi...

June 28, 2021 1 EN
 PRESS RELEASE
Free
CHMA CHIASMA

Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOW...

Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly --Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patient...

May 27, 2021 1 EN
 PRESS RELEASE
Free
CHMA CHIASMA

Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at...

Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences -- New clinical data accepted for oral and e-Poster presentation at AACE -- -- e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting -- NEEDHAM, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently t...

May 20, 2021 1 EN
 PRESS RELEASE
Free
CHMA CHIASMA

Chiasma Reports First Quarter Financial Results and Announced Agreemen...

Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt Announced agreement to merge with Amryt Combination to create a global commercial stage rare and orphan disease leader with a diversified portfolio of therapies and a meaningful late-stage development pipeline Q1 2021 Net Product Revenues of $1.9M, a 100% increase over Q4 2020 Achieved payor coverage of MYCAPSSA for over 185 million lives Submitted an Investigational New Drug (IND) application for the study of MYCAPSSA in patients with carcinoid syndrome associated with Neuroendocrine Tum...

May 5, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch